Open Access

SIRT1 and gynecological malignancies (Review)

  • Authors:
    • Jiayu Chen
    • Houzao Chen
    • Lingya Pan
  • View Affiliations

  • Published online on: February 24, 2021
  • Article Number: 43
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Sirtuin 1 (SIRT1), a member of the sirtuin protein family, is a nicotinamide adenine dinucleotide (NAD+)‑dependent type III histone deacetylase and mono‑ADP‑ribosyltransferase. SIRT1 can deacetylate histones (H1, H3, and H4) and non‑histone proteins, and it is widely involved in various physiological and pathological processes in the body, including metabolism, aging, transcription, DNA damage and repair, apoptosis, cell cycle regulation, inflammation and cancer. Research has shown that SIRT1 is involved in tumorigenesis, tumor metastasis and chemotherapy resistance, but it exerts opposing effects and plays different roles in different pathogenic processes. Recent studies have demonstrated that SIRT1 may be implicated in the pathogenesis, development, treatment and prognosis of tumors; however, its role in gynecological tumors remains elusive. The aim of the present review was to summarize the pathogenic roles of SIRT1 in cancer, and to provide what is, to the best of our knowledge, the first review of recent advances involving SIRT1 in cervical cancer, endometrial cancer (EC) and ovarian cancer (OC). In addition, the critical research gaps regarding SIRT1, particularly its potential involvement in the concurrence of EC and cervical cancer and its antagonistic effect against poly(ADP‑ribose) polymerase inhibitors in OC, were highlighted.
View Figures
View References

Related Articles

Journal Cover

Volume 45 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Spandidos Publications style
Chen J, Chen H and Pan L: SIRT1 and gynecological malignancies (Review). Oncol Rep 45: 43, 2021
Chen, J., Chen, H., & Pan, L. (2021). SIRT1 and gynecological malignancies (Review). Oncology Reports, 45, 43.
Chen, J., Chen, H., Pan, L."SIRT1 and gynecological malignancies (Review)". Oncology Reports 45.4 (2021): 43.
Chen, J., Chen, H., Pan, L."SIRT1 and gynecological malignancies (Review)". Oncology Reports 45, no. 4 (2021): 43.